Screener
Neurocrine Biosciences NBIX Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
FAQ
- What is Neurocrine Biosciences's operating lease liabilities (current)?
- Neurocrine Biosciences (NBIX) reported operating lease liabilities (current) of $57.3M in Q1 2026.
- How has Neurocrine Biosciences's operating lease liabilities (current) changed year-over-year?
- Neurocrine Biosciences's operating lease liabilities (current) increased by 25.7% year-over-year, from $45.6M to $57.3M.
- What is the long-term trend for Neurocrine Biosciences's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's operating lease liabilities (current) has grown at a 40.3% compound annual growth rate (CAGR), from $10.3M to $56M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about Neurocrine Biosciences's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude